{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:12:09Z","timestamp":1790507529740,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T00:00:00Z","timestamp":1543881600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00345-018-2592-0","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T11:48:04Z","timestamp":1543924084000},"page":"2031-2040","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC)"],"prefix":"10.1007","volume":"37","author":[{"given":"Ryan P.","family":"Werntz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Adamic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,4]]},"reference":[{"key":"2592_CR1","first-page":"5","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA: A Cancer J Clin 65:5\u201329","journal-title":"CA: A Cancer J Clin"},{"key":"2592_CR2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden APM, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466\u2013475. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.031 (discussion 475\u20137)","journal-title":"Eur Urol"},{"key":"2592_CR3","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E et al (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette\u2013Guerin: the CUETO scoring model. J Urol 182:2195\u20132203. https:\/\/doi.org\/10.1016\/j.juro.2009.07.016","journal-title":"J Urol"},{"key":"2592_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol 196:1021\u20131029. https:\/\/doi.org\/10.1016\/j.juro.2016.06.049","journal-title":"J Urol"},{"key":"2592_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/00005392-199907000-00018","volume":"162","author":"HW Herr","year":"1999","unstructured":"Herr HW (1999) The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162:74\u201376. https:\/\/doi.org\/10.1097\/00005392-199907000-00018","journal-title":"J Urol"},{"key":"2592_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.eururo.2010.03.007","volume":"58","author":"RT Divrik","year":"2010","unstructured":"Divrik RT, Sahin AF, Yildirim U et al (2010) Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 58:185\u2013190. https:\/\/doi.org\/10.1016\/j.eururo.2010.03.007","journal-title":"Eur Urol"},{"issue":"Suppl 4","key":"2592_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bju.13265","volume":"117","author":"R Gendy","year":"2016","unstructured":"Gendy R, Delprado W, Brenner P et al (2016) Repeat transurethral resection for non-muscle-invasive bladder cancer: a contemporary series. BJU Int 117(Suppl 4):54\u201359. https:\/\/doi.org\/10.1111\/bju.13265","journal-title":"BJU Int"},{"key":"2592_CR8","doi-asserted-by":"publisher","first-page":"e0189354","DOI":"10.1371\/journal.pone.0189354","volume":"12","author":"BS Tae","year":"2017","unstructured":"Tae BS, Jeong CW, Kwak C et al (2017) Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer. PLoS One 12:e0189354. https:\/\/doi.org\/10.1371\/journal.pone.0189354","journal-title":"PLoS One"},{"key":"2592_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.juro.2006.08.070","volume":"177","author":"HW Herr","year":"2007","unstructured":"Herr HW, Donat SM, Dalbagni G (2007) Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol 177:75\u201379. https:\/\/doi.org\/10.1016\/j.juro.2006.08.070 (discussion 79)","journal-title":"J Urol"},{"key":"2592_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","volume":"158","author":"MS Cookson","year":"1997","unstructured":"Cookson MS, Herr HW, Zhang ZF et al (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158:62\u201367. https:\/\/doi.org\/10.1097\/00005392-199707000-00017","journal-title":"J Urol"},{"key":"2592_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S1077-9108(08)70376-1","volume":"2007","author":"R Dhir","year":"2007","unstructured":"Dhir R (2007) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Yearb Pathol Lab Med 2007:192\u2013193. https:\/\/doi.org\/10.1016\/S1077-9108(08)70376-1","journal-title":"Yearb Pathol Lab Med"},{"key":"2592_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","volume":"60","author":"J Fernandez-Gomez","year":"2011","unstructured":"Fernandez-Gomez J, Madero R, Solsona E et al (2011) The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette\u2013Gu\u00e9rin: external validation of the EORTC risk tables. Eur Urol 60:423\u2013430. https:\/\/doi.org\/10.1016\/j.eururo.2011.05.033","journal-title":"Eur Urol"},{"key":"2592_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1200\/JCO.2014.57.6967","volume":"33","author":"W Martin-Doyle","year":"2015","unstructured":"Martin-Doyle W, Leow JJ, Orsola A et al (2015) Improving selection criteria for early cystectomy in high-grade T1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol 33:643\u2013650. https:\/\/doi.org\/10.1200\/JCO.2014.57.6967","journal-title":"J Clin Oncol"},{"key":"2592_CR14","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1097\/01.ju.0000181814.73466.14","volume":"174","author":"DI Daniltchenko","year":"2005","unstructured":"Daniltchenko DI, Riedl CR, Sachs MD et al (2005) Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 174:2129\u20132133. https:\/\/doi.org\/10.1097\/01.ju.0000181814.73466.14 (discussion 2133)","journal-title":"J Urol"},{"key":"2592_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.juro.2007.03.034","volume":"178","author":"HB Grossman","year":"2007","unstructured":"Grossman HB, Gomella L, Fradet Y et al (2007) A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 178:62\u201367. https:\/\/doi.org\/10.1016\/j.juro.2007.03.034","journal-title":"J Urol"},{"key":"2592_CR16","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","volume":"64","author":"M Burger","year":"2013","unstructured":"Burger M, Grossman HB, Droller M et al (2013) Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 64:846\u2013854. https:\/\/doi.org\/10.1016\/j.eururo.2013.03.059","journal-title":"Eur Urol"},{"key":"2592_CR17","doi-asserted-by":"publisher","first-page":"e74142","DOI":"10.1371\/journal.pone.0074142","volume":"8","author":"H Yuan","year":"2013","unstructured":"Yuan H, Qiu J, Liu L et al (2013) Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials. PLoS One 8:e74142. https:\/\/doi.org\/10.1371\/journal.pone.0074142","journal-title":"PLoS One"},{"key":"2592_CR18","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1016\/j.juro.2016.10.101","volume":"197","author":"A Morales","year":"2017","unstructured":"Morales A, Eidinger D, Bruce AW (2017) Intracavitary Bacillus Calmette\u2013Guerin in the treatment of superficial bladder tumors. J Urol 197:S142\u2013S145. https:\/\/doi.org\/10.1016\/j.juro.2016.10.101","journal-title":"J Urol"},{"key":"2592_CR19","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, Bohle A, Burger M et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447\u2013461. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.041","journal-title":"Eur Urol"},{"key":"2592_CR20","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD et al (2000) Maintenance bacillus Calmette\u2013Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163:1124\u20131129","journal-title":"J Urol"},{"key":"2592_CR21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, Brausi M, Sylvester R et al (2013) Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette\u2013Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1\u00a0year versus 3\u00a0years of maintenance. Eur Urol 63:462\u2013472. https:\/\/doi.org\/10.1016\/j.eururo.2012.10.039","journal-title":"Eur Urol"},{"key":"2592_CR22","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","volume":"169","author":"HW Herr","year":"2003","unstructured":"Herr HW, Dalbagni G (2003) Defining bacillus Calmette\u2013Guerin refractory superficial bladder tumors. J Urol 169:1706\u20131708. https:\/\/doi.org\/10.1097\/01.ju.0000062605.92268.c6","journal-title":"J Urol"},{"key":"2592_CR23","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.eururo.2016.02.031","volume":"70","author":"CO Mmeje","year":"2016","unstructured":"Mmeje CO, Guo CC, Shah JB et al (2016) Papillary recurrence of bladder cancer at first evaluation after induction Bacillus Calmette\u2013Gu\u00e9rin therapy: implication for clinical trial design. Eur Urol 70:778\u2013785. https:\/\/doi.org\/10.1016\/j.eururo.2016.02.031","journal-title":"Eur Urol"},{"key":"2592_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0022-5347(17)32741-6","volume":"152","author":"RB Nadler","year":"1994","unstructured":"Nadler RB, Catalona WJ, Hudson MA, Ratliff TL (1994) Durability of the tumor-free response for intravesical bacillus Calmette\u2013Guerin therapy. J Urol 152:367\u2013373","journal-title":"J Urol"},{"key":"2592_CR25","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0094-0143(21)00424-9","volume":"19","author":"DL Lamm","year":"1992","unstructured":"Lamm DL (1992) Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin N Am 19:573\u2013580","journal-title":"Urol Clin N Am"},{"key":"2592_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0090-4295(96)90059-X","volume":"48","author":"MF Sarosdy","year":"1996","unstructured":"Sarosdy MF, Lowe BA, Schellhammer PF et al (1996) Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology 48:21\u201327. https:\/\/doi.org\/10.1016\/S0090-4295(96)90059-X","journal-title":"Urology"},{"key":"2592_CR27","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S0090-4295(97)00510-4","volume":"51","author":"MF Sarosdy","year":"1998","unstructured":"Sarosdy MF, Manyak MJ, Sagalowsky AI et al (1998) Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette\u2013Gu\u00e9rin. Urology 51:226\u2013231. https:\/\/doi.org\/10.1016\/S0090-4295(97)00510-4","journal-title":"Urology"},{"key":"2592_CR28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0090-4295(96)00621-8","volume":"49","author":"RE Greenberg","year":"1997","unstructured":"Greenberg RE, Bahnson RR, Wood D et al (1997) Initial report on intraves1\u00a0cal administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology 49:471\u2013475. https:\/\/doi.org\/10.1016\/S0090-4295(96)00621-8","journal-title":"Urology"},{"key":"2592_CR29","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","volume":"31","author":"CPN Dinney","year":"2013","unstructured":"Dinney CPN, Greenberg RE, Steinberg GD (2013) Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette\u2013Gu\u00e9rin. Urol Oncol 31:1635\u20131642. https:\/\/doi.org\/10.1016\/j.urolonc.2012.04.010","journal-title":"Urol Oncol"},{"key":"2592_CR30","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","volume":"163","author":"G Steinberg","year":"2000","unstructured":"Steinberg G, Bahnson R, Brosman S et al (2000) Efficacy and safety of valrubicin for the treatment of Bacillus Calmette\u2013Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 163:761\u2013767","journal-title":"J Urol"},{"key":"2592_CR31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0090-4295(96)00455-4","volume":"49","author":"J Portillo","year":"1997","unstructured":"Portillo J, Martin B, Hernandez R et al (1997) Results at 43\u00a0months\u2019 follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology 49:187\u2013190. https:\/\/doi.org\/10.1016\/S0090-4295(96)00455-4","journal-title":"Urology"},{"key":"2592_CR32","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S1078-1439(03)00012-7","volume":"21","author":"JS Lam","year":"2003","unstructured":"Lam JS, Benson MC, O\u2019Donnell MA et al (2003) Bacillus Calmete-Gu\u00e9rin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol 21:354\u2013360","journal-title":"Urol Oncol"},{"key":"2592_CR33","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","volume":"166","author":"MA O\u2019Donnell","year":"2001","unstructured":"O\u2019Donnell MA, Krohn J, DeWolf WC (2001) Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette\u2013Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette\u2013Guerin alone previously failed. J Urol 166:1300\u20131304 (discussion 1304\u20135)","journal-title":"J Urol"},{"key":"2592_CR34","first-page":"1790","volume":"10","author":"SP Punnen","year":"2003","unstructured":"Punnen SP, Chin JL, Jewett MAS (2003) Management of bacillus Calmette\u2013Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy. Can J Urol 10:1790\u20131795","journal-title":"Can J Urol"},{"key":"2592_CR35","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.juro.2011.04.073","volume":"186","author":"HM Rosevear","year":"2011","unstructured":"Rosevear HM, Lightfoot AJ, Birusingh KK et al (2011) Factors affecting response to bacillus Calmette\u2013Gu\u00e9rin plus interferon for urothelial carcinoma in situ. J Urol 186:817\u2013823. https:\/\/doi.org\/10.1016\/j.juro.2011.04.073","journal-title":"J Urol"},{"key":"2592_CR36","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","volume":"182","author":"O Nativ","year":"2009","unstructured":"Nativ O, Witjes JA, Hendricksen K et al (2009) Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette\u2013Guerin. J Urol 182:1313\u20131317. https:\/\/doi.org\/10.1016\/j.juro.2009.06.017","journal-title":"J Urol"},{"key":"2592_CR37","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00345-018-2199-5","volume":"36","author":"Z Liu","year":"2018","unstructured":"Liu Z, Ye Y, Li X et al (2018) The effects of intra-arterial chemotherapy on bladder preservation in patients with T1 stage bladder cancer. World J Urol 36:1191\u20131200. https:\/\/doi.org\/10.1007\/s00345-018-2199-5","journal-title":"World J Urol"},{"key":"2592_CR38","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","volume":"190","author":"EC Skinner","year":"2013","unstructured":"Skinner EC, Goldman B, Sakr WA et al (2013) SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette\u2013Gu\u00e9rin. J Urol 190:1200\u20131204. https:\/\/doi.org\/10.1016\/j.juro.2013.04.031","journal-title":"J Urol"},{"key":"2592_CR39","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.eururo.2015.02.032","volume":"68","author":"ED Carosella","year":"2015","unstructured":"Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F (2015) A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1\/PD-L1, and HLA-G. Eur Urol 68:267\u2013279. https:\/\/doi.org\/10.1016\/j.eururo.2015.02.032","journal-title":"Eur Urol"},{"key":"2592_CR40","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1038\/s41585-018-0055-4","volume":"49","author":"C Pettenati","year":"2018","unstructured":"Pettenati C, Ingersoll MA (2018) Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol 49:1374. https:\/\/doi.org\/10.1038\/s41585-018-0055-4","journal-title":"Nat Rev Urol"},{"key":"2592_CR41","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1200\/JCO.2017.35.6_suppl.319","volume":"35","author":"GD Steinberg","year":"2017","unstructured":"Steinberg GD, Shore ND, Karsh LI et al (2017) Immune response results of vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase II trial in patients with non-muscle invasive bladder cancer (NMIBC). J Clin Oncol 35:319. https:\/\/doi.org\/10.1200\/JCO.2017.35.6_suppl.319","journal-title":"J Clin Oncol"},{"key":"2592_CR42","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1016\/j.juro.2017.02.495","volume":"197","author":"T Sanford","year":"2017","unstructured":"Sanford T, Donahue R, Jochems C et al (2017) MP15-10 immunologic response to a therapeutic cancer vaccine (PANVAC): initial results from a randomized phase 2 clinical trial. J Urol 197:e174. https:\/\/doi.org\/10.1016\/j.juro.2017.02.495","journal-title":"J Urol"},{"key":"2592_CR43","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","volume":"190","author":"CPN Dinney","year":"2013","unstructured":"Dinney CPN, Fisher MB, Navai N et al (2013) Phase I trial of intravesical recombinant adenovirus mediated interferon-\u03b12b formulated in Syn3 for Bacillus Calmette\u2013Gu\u00e9rin failures in nonmuscle invasive bladder cancer. J Urol 190:850\u2013856. https:\/\/doi.org\/10.1016\/j.juro.2013.03.030","journal-title":"J Urol"},{"key":"2592_CR44","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1200\/JCO.2017.35.6_suppl.279","volume":"35","author":"SA Boorjian","year":"2017","unstructured":"Boorjian SA, Shore ND, Canter D et al (2017) Intravesical rad-IFN\u03b1\/Syn3 for patients with high-grade, bacillus Calmette\u2013Gu\u00e9rin (BCG) refractory or relapsed non-muscle invasive bladder cancer: a phase II randomized study. J Clin Oncol 35:279. https:\/\/doi.org\/10.1200\/JCO.2017.35.6_suppl.279","journal-title":"J Clin Oncol"},{"key":"2592_CR45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ucl.2015.02.001","volume":"42","author":"BE Boehm","year":"2015","unstructured":"Boehm BE, Svatek RS (2015) Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancer. Urol Clin N Am 42:159\u2013168. https:\/\/doi.org\/10.1016\/j.ucl.2015.02.001 (vii)","journal-title":"Urol Clin N Am"},{"key":"2592_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.07.005","author":"VT Packiam","year":"2017","unstructured":"Packiam VT, Lamm DL, Barocas DA et al (2017) An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. Urologic oncology. https:\/\/doi.org\/10.1016\/j.urolonc.2017.07.005","journal-title":"Urologic oncology"},{"key":"2592_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/iju.IJU_296_17","volume":"34","author":"KN Rayn","year":"2018","unstructured":"Rayn KN, Hale GR, Grave GP-L, Agarwal PK (2018) New therapies in nonmuscle invasive bladder cancer treatment. Indian J Urol 34:11\u201319. https:\/\/doi.org\/10.4103\/iju.IJU_296_17","journal-title":"Indian J Urol"},{"key":"2592_CR48","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.urology.2017.01.018","volume":"103","author":"DJ Robins","year":"2017","unstructured":"Robins DJ, Sui W, Matulay JT et al (2017) Long-term survival outcomes with intravesical nanoparticle albumin-bound paclitaxel for recurrent non-muscle-invasive bladder cancer after previous Bacillus Calmette\u2013Gu\u00e9rin therapy. Urology 103:149\u2013153. https:\/\/doi.org\/10.1016\/j.urology.2017.01.018","journal-title":"Urology"},{"key":"2592_CR49","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ucl.2015.02.002","volume":"42","author":"C Premo","year":"2015","unstructured":"Premo C, Apolo AB, Agarwal PK, Citrin DE (2015) Trimodality therapy in bladder cancer. Urol Clin N Am 42:169\u2013180. https:\/\/doi.org\/10.1016\/j.ucl.2015.02.002","journal-title":"Urol Clin N Am"},{"key":"2592_CR50","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.euf.2018.07.017","volume":"4","author":"SEM Raby","year":"2018","unstructured":"Raby SEM, Choudhury A (2018) Radiotherapy for high-grade T1 bladder cancer. Eur Urol Focus 4:506\u2013508. https:\/\/doi.org\/10.1016\/j.euf.2018.07.017","journal-title":"Eur Urol Focus"},{"key":"2592_CR51","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","volume":"11","author":"Y Liu","year":"2018","unstructured":"Liu Y, Dong Y, Kong L et al (2018) Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol 11:104. https:\/\/doi.org\/10.1186\/s13045-018-0647-8","journal-title":"J Hematol Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2592-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-018-2592-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2592-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T14:05:29Z","timestamp":1662559529000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-018-2592-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,4]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["2592"],"URL":"https:\/\/doi.org\/10.1007\/s00345-018-2592-0","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,4]]},"assertion":[{"value":"7 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Gary Steinberg: I am a scientific advisor\/consultant for the following companies: Heat Biologics, Cold Genesys, PhotoCure, Merck, Roche\/Genentech, Taris Biomedical, MDxHealth, Fidia Farmaceuticals, Urogen, Spectrum Pharmaceuticals, Biocancell, Epivax Oncology, Natera, FKD, Synergo, BMS, Boston Scientific, Ferring Pharmaceuticals, QED. Ryan Werntz: none. Brittany Adamic: none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}